Neomycin Sulfate, Usp + Nystatin, Usp + Thiostrepton, Usp + Triamcinolone Acetonide, Usp

Verify with FDA CVM →

23 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
23
Total Reports
1
Deaths Reported
430.0%
Death Rate

Active Ingredients

Neomycin Sulfate, UspNystatin, UspThiostrepton, UspTriamcinolone Acetonide, Usp

Administration Routes

UnknownIntraocularOral

Species Affected

Dog 19
Cat 3
Human 1

Most Affected Breeds

Unknown 5
Retriever - Labrador 4
Terrier - Boston 2
Bulldog - French 1
Domestic Mediumhair 1
Poodle (unspecified) 1
Shepherd Dog - Belgian Malinois 1
Doberman Pinscher 1
Maine Coon 1
Shepherd Dog - German 1

Most Reported Reactions

Loss of hearing 14
Vomiting 2
Loose stool 2
Death 1
Blood in urine 1
Medication error 1
Eye irritation 1
Generalised skin reaction 1
Polydipsia 1
Scleritis 1
Cloudy eye (for Miosis, Mydriasis, Anisocoria, Nystagmus - see 'Neurological') 1
Swollen lymph node 1

Outcome Breakdown

Ongoing
13 (54.2%)
Outcome Unknown
8 (33.3%)
Recovered/Normal
2 (8.3%)
Died
1 (4.2%)

Data Summary

Metric Value
Total adverse event reports 23
Reports involving death 1
Case-fatality rate (reported events) 430.0%
Distinct species in reports 3
Distinct breeds in reports 15
Distinct reactions reported 13
Active ingredients on file 4

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Neomycin Sulfate, Usp + Nystatin, Usp + Thiostrepton, Usp + Triamcinolone Acetonide, Usp Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 23 adverse event reports referencing Neomycin Sulfate, Usp + Nystatin, Usp + Thiostrepton, Usp + Triamcinolone Acetonide, Usp, including 1 reports in which the animal died — a 430.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Neomycin Sulfate, Usp, Nystatin, Usp, Thiostrepton, Usp, Triamcinolone Acetonide, Usp. Reported administration routes include Unknown, Intraocular, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Neomycin Sulfate, Usp + Nystatin, Usp + Thiostrepton, Usp + Triamcinolone Acetonide, Usp reports are Dog (19 reports), Cat (3 reports), Human (1 reports), with Dog accounting for the largest share. Within those species, Unknown (5), Retriever - Labrador (4), Terrier - Boston (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Neomycin Sulfate, Usp + Nystatin, Usp + Thiostrepton, Usp + Triamcinolone Acetonide, Usp are Loss of hearing (14), Vomiting (2), Loose stool (2), Death (1). Of the 24 reports with a coded outcome, Ongoing is the leading category at 54.2%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Neomycin Sulfate, Usp + Nystatin, Usp + Thiostrepton, Usp + Triamcinolone Acetonide, Usp.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial